Following the old adage "Although processing is complicated, you will not dare to save labor, although the taste is expensive, you will not dare to reduce materials", Tong Ren Tang once again encountered a crisis of quality trust. Recently, some media reported that Beijing Tongrentang was on the black list of quality inspection six times a year, which involved unqualified sampling results of related products and the sale of inferior drugs.
In this regard, Tongrentang, a listed company, issued a clarification announcement on February 18, saying that the "roasted licorice", "scalded bones and broken bones" and "prepared rehmannia root" concerned by the media were produced and sold by Tongrentang (Bozhou) Pieces Company, not the products of the company; Our company has never produced this kind of decoction pieces.
Fall into a quality crisis again
It is understood that the sampling inspection results of roasted licorice produced by Beijing Tongrentang (Bozhou) Pieces Co., Ltd. (hereinafter referred to as Tongrentang (Bozhou) Pieces Co., Ltd.) in Tianjin are that the content determination items do not conform to the relevant provisions of the Pharmacopoeia of China (20 15 edition), and the sampling inspection results of Rhizoma Drynariae in Guizhou Province are unqualified, and the sampling inspection results of Radix Rehmanniae in Hubei Province are unqualified. Beijing Tongrentang Pharmaceutical Co., Ltd. failed to pass the random inspection of the drug Jiawei Zuojin Pill due to the difference in quantity, and Tongrentang Zibo Pharmacy was fined for selling inferior drugs.
On February 18, Tongrentang introduced in the clarification announcement that Tongrentang (Bozhou) Pieces Company is a Chinese herbal pieces production enterprise controlled by Beijing Tongrentang Ginseng Investment Group Co., Ltd., a subsidiary of Beijing Tongrentang (Group) Co., Ltd. (hereinafter referred to as Tongrentang Group). The media pay attention to the fact that "Radix Glycyrrhizae Preparata", "Rhizoma Drynariae", "Radix Rehmanniae Preparata" and "Potentilla discolor" are all produced and sold by Tongrentang (Bozhou) Pieces Company, not our products. Our company has never produced this kind of decoction pieces.
However, a company person close to Tong Ren Tang (Bozhou) pieces told reporters that the above statement is also biased. Potentilla discolor is not produced by the company, but a fake company product.
In addition, the listed company Tongrentang also introduced that Beijing Tongrentang Pharmaceutical Co., Ltd. is a Sino-foreign joint venture under Tongrentang Group Co., Ltd., and its products do not overlap with our company. The "Jiawei Zuojin Pill" concerned by the media is produced by our company, not our company's products.
Regarding the sale of inferior drugs by Tong Ren Tang Zibo Pharmacy, Tong Ren Tang said that the pharmacy purchased red ginseng produced by enterprises other than Tong Ren Tang, and the channels were legal and compliant. The manufacturer's license is complete, and the quality inspection report of red ginseng products is provided. Later, during sampling inspection, it was found that the ginsenoside content of the product was not up to standard, and Tongrentang Zibo Pharmacy had promptly terminated all business dealings with the manufacturer.
The quality of traditional Chinese medicine products attracts people's attention
While the product quality of the time-honored Tongrentang attracts social attention, Chinese medicine manufacturers, including Yunnan Baiyao, also face quality crises repeatedly.
"Chinese herbal pieces are an important part of the Chinese medicine industry chain, but in recent years, Chinese herbal pieces have been repeatedly exposed to quality problems. The quality crisis of well-known enterprises reflects the problems faced by the entire Chinese medicine industry. " ? Shi Lichen, the head of Beijing Chen Ding Medicine Management Consulting Center, told the Securities Daily reporter that the state has intensified the flight inspection of the Chinese medicine industry in recent years.
On February 9th, China Food and Drug Administration issued the Notice on Unqualified 54 batches of Chinese Herbal Pieces, which involved a variety of commonly used drugs such as Radix Isatidis. Unqualified items included properties, content determination, sulfur dioxide residue and so on. The State Food and Drug Administration of the United States said that the food and drug administrations of relevant provinces (autonomous regions and municipalities) have taken control measures such as sealing up and detaining, requiring enterprises to suspend sales and use, recall products and carry out rectification. The production enterprises that produce unqualified pieces of decoction shall be given heavier punishment.
In Shi Lichen's view, the development of Chinese medicine industry has attracted the attention of the state, and the quality of products must be strictly observed. However, it is difficult to ensure the quality of Chinese medicine products only by the flight inspection of the regulatory authorities. Shi Lichen believes: "A set of standards should be formulated for the entire Chinese medicine industry chain, and production, procurement, circulation, warehousing and sales should be carried out according to the standards; Set up inspection institutions in large Chinese medicine enterprises and production bases; In addition, it is necessary to strengthen penalties for illegal production enterprises. "